Abstract: Objective: To explore the therapeutic effects of ticagrelor on the patients with acute coronary syndrome(ACS).Methods: One hundred and seven ACS patients were randomly divided into the ticagrelor group(group A,50 cases) and clopidogrel group(group B,57 cases).The clinical data of two groups were collected.The platelet aggregation rates in two groups were detected before and after 2 h,4 h,24 h,7 d and 30 d of medicine.The major adverse reaction and adverse cardiac event within 30 days were observed.Results: The platelet aggregation rates in group A after 2 h,4 h,24 h,7 d and 30 d of medicine were significantly lower than that in group B(P < 0.05 to P < 0.01),and the platelet aggregation rates in two groups before medicine were significantly lower than that in different time points after medicine(P < 0.01).The differences of the incidences of major adverse reaction and adverse cardiac event between two groups were not statistically significant(P > 0.05).Conclusions: The effect of the ticagrelor in inhibiting platelet in patients with ACS is better than that of clopidogrel,and the securities of two are similar.